ANXA2 and neoplasm: A phase 2 clinical trial involving GVAX (allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine) identified Annexin A2 (AnxA2) from the sera of patients with PDA, as a metastasis-associated protein.